Browse Studies — Arctuva

Phase 1

An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorecta…

Unresectable Metastatic Colorectal Cancer

Estimated

~$10 – $7,500

Celyad Oncology SANCT03692429

Phase 1

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of…

Unresectable Metastatic Colorectal CancerUnresectable Locally Advanced Colorectal Cancer

Estimated

~$10 – $8,750

Brenus PharmaNCT06934538

Phase 1

An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer admi…

Unresectable Metastatic Colorectal Cancer

Estimated

~$10 – $7,500

Celyad Oncology SANCT04991948